Most Shorted Stocks
COGT is part of our most shorted stocks screen list, indicating it has a high short interest.
COGENT BIOSCIENCES INC (COGT) Stock Price & Overview
NASDAQ:COGT • US19240Q2012
Current stock price
36.39 USD
-0.34 (-0.93%)
At close:
36.18 USD
-0.21 (-0.58%)
Pre-Market:
The current stock price of COGT is 36.39 USD. Today COGT is down by -0.93%. In the past month the price increased by 4.09%. In the past year, price increased by 684.27%.
COGT Key Statistics
52-Week Range4.55 - 43.73
Current COGT stock price positioned within its 52-week range.
1-Month Range33.82 - 39.41
Current COGT stock price positioned within its 1-month range.
- Market Cap
- 5.906B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.18
- Dividend Yield
- N/A
COGT Stock Performance
Today
-0.93%
1 Week
+0.19%
1 Month
+4.09%
3 Months
-0.79%
Longer-term
6 Months +140.52%
1 Year +684.27%
2 Years +459.85%
3 Years +238.20%
5 Years +318.76%
10 Years N/A
COGT Stock Chart
COGT Stock Screens
COGT currently appears in the following ChartMill screener lists.
COGT Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to COGT. When comparing the yearly performance of all stocks, COGT is one of the better performing stocks in the market, outperforming 99.32% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
COGT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to COGT. COGT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
COGT Earnings
Next Earnings DateMay 12, 2026
Last Earnings DateFeb 17, 2026
PeriodQ4 / 2025
EPS Reported-$0.64
Revenue Reported
EPS Surprise -20.90%
Revenue Surprise %
COGT Forecast & Estimates
19 analysts have analysed COGT and the average price target is 54.34 USD. This implies a price increase of 49.32% is expected in the next year compared to the current price of 36.39.
Analysts
Analysts85.26
Price Target54.34 (49.33%)
EPS Next Y-1.84%
Revenue Next YearN/A
COGT Groups
Sector & Classification
COGT Financial Highlights
Over the last trailing twelve months COGT reported a non-GAAP Earnings per Share(EPS) of -2.18. The EPS decreased by -10.91% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-277.80M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -29.63% | ||
| ROE | -43.65% | ||
| Debt/Equity | 0.35 |
Chartmill High Growth Momentum
EPS Q2Q%-429.17%
Sales Q2Q%N/A
EPS 1Y (TTM)-10.91%
Revenue 1Y (TTM)N/A
COGT Ownership
Ownership
Inst Owners105.89%
Shares162.31M
Float160.11M
Ins Owners0.86%
Short Float %10.88%
Short Ratio8.42
COGT Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.52 | 354.636B | ||
| AMGN | AMGEN INC | 15.15 | 186.69B | ||
| GILD | GILEAD SCIENCES INC | 15.03 | 164.958B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.47 | 111.326B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.92 | 78.928B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.5 | 41.441B | ||
| INSM | INSMED INC | N/A | 31.186B | ||
| NTRA | NATERA INC | N/A | 29.449B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.041B | ||
| BIIB | BIOGEN INC | 11.79 | 27.895B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.65 | 25.171B | ||
| MRNA | MODERNA INC | N/A | 22.05B | ||
| INCY | INCYTE CORP | 12.5 | 19.252B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About COGT
Company Profile
Cogent Biosciences, Inc. is a biotechnology company, which engages in the development of precision therapies for genetically defined diseases. The company is headquartered in Waltham, Massachusetts and currently employs 258 full-time employees. The company went IPO on 2018-03-29. The firm is focused on developing precision therapies for genetically defined diseases. The Company’s clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. In addition to bezuclastinib, the Company is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases initially targeting mutations in FGFR2, ErbB2 and PI3Kα. SUMMIT is its randomized, global, multicenter, double-blind, placebo-controlled, multi-part Phase II clinical trial for patients with Non-AdvSM. APEX is an open-label, global, multicenter study evaluating the safety, efficacy, pharmacokinetic, and pharmacodynamic profiles of bezuclastinib.
Company Info
IPO: 2018-03-29
COGENT BIOSCIENCES INC
275 Wyman Street, 3rd Floor
Waltham MASSACHUSETTS 02140 US
CEO: Andrew Robbins
Employees: 258
Phone: 16179455576
COGENT BIOSCIENCES INC / COGT FAQ
What does COGT do?
Cogent Biosciences, Inc. is a biotechnology company, which engages in the development of precision therapies for genetically defined diseases. The company is headquartered in Waltham, Massachusetts and currently employs 258 full-time employees. The company went IPO on 2018-03-29. The firm is focused on developing precision therapies for genetically defined diseases. The Company’s clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. In addition to bezuclastinib, the Company is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases initially targeting mutations in FGFR2, ErbB2 and PI3Kα. SUMMIT is its randomized, global, multicenter, double-blind, placebo-controlled, multi-part Phase II clinical trial for patients with Non-AdvSM. APEX is an open-label, global, multicenter study evaluating the safety, efficacy, pharmacokinetic, and pharmacodynamic profiles of bezuclastinib.
Can you provide the latest stock price for COGENT BIOSCIENCES INC?
The current stock price of COGT is 36.39 USD. The price decreased by -0.93% in the last trading session.
Does COGENT BIOSCIENCES INC pay dividends?
COGT does not pay a dividend.
How is the ChartMill rating for COGENT BIOSCIENCES INC?
COGT has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What sector and industry does COGENT BIOSCIENCES INC belong to?
COGENT BIOSCIENCES INC (COGT) operates in the Health Care sector and the Biotechnology industry.
Should I buy COGT stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on COGT.
How many employees does COGENT BIOSCIENCES INC have?
COGENT BIOSCIENCES INC (COGT) currently has 258 employees.